We aim to explore effects of
Ketotifen on metabolic profiles,
inflammation and oxidative stress. Sprague Dawley (SD) male rats were randomly divided into normal control group (NC) and experimental groups, and experimental group rats were fed with high-
sugar and fat diet for 6 weeks. Then, experimental group rats were divided into diabetes group (DM) and
ketotifen treatment group (KT). KT group was given
ketotifen via Intragastric for 8 weeks with the dosage of 0.09 mg/kg/d. Fasting plasma
glucose (FPG) was measured using
glucose oxidase-
phenol amino
phenazone method. Fasting
insulin (FINS), total
cholesterol (TC),
triglyceride (TG),
low-density lipoprotein (
LDL),
high-density lipoprotein (HDL),
interleukin-6 (IL-6) and
tumor necrosis factor-α (TNF-α) were tested by
enzyme-linked
immunosorbent assay.
Malondialdehyde (MDA) and
superoxide dismutase (SOD) were quantified by spectrophotometer method. Before
Ketotifen administration, compared with NC group, DM and KT groups showed significantly high levels of
body weight, FPG, FINS, HOMA-IR, TC, TG,
LDL,
IL-6, TNF-α and MDA, and lower levels of HDL and SOD (All p <0.05). After 4 weeks of
Ketotifen administration, levels of
body weight, FPG, FINS, HOMA-IR, TC, TG,
LDL,
IL-6, TNF-α in KT group decreased significantly, and levels of HDL and SOD elevated significantly (All p <0.05). After 8 weeks of
Ketotifen administration, levels of
body weight, FPG, FINS, HOMA-IR, TC, TG,
LDL,
IL-6, TNF-α and MDA in KT group decreased more obviously, and levels of HDL and SOD elevated significantly further (All p <0.05).
Ketotifen improved metabolic profiles, and ameliorated status of
inflammation and oxidative stress.